Report: Drug Innovations Could Transform Alzheimers Medication Market

A recent study projects disease modifying drugs could hit the market and set new industry standards by 2015.

The patent expiry of all four existing EMEA approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth of the European AD medication market. However, the approval of next generation therapies that can delay disease progression and restore cognitive functions are expected to revive opportunities in the market from 2015 to 2018.

No votes yet
Syndicate content